Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.

 

Important Public Notice: ANCC Magnet Recognition Program® - Site Visit through November 4, 2022. Click here to learn more.

MENU

Thomas J. Galloway, MD

Department of Radiation Oncology
Thomas Galloway, MD
4.8
(4.8/5) 77 Patient Satisfaction Ratings

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Associate Professor, Department of Radiation Oncology

Chief, Division of Head and Neck Radiation Oncology

Medical Director, Clinical Research

 

Specialties

Head & Neck Cancer;  Melanoma;  Skin Cancer;  Thyroid Cancer

Treatment Focus

  • Intensity modulated radiation therapy
  • Stereotactic body radiation therapy
  • Modulated electron beam therapy
  • Interstitial brachytherapy
  • Rotational arc therapy

Research Program

Key Awards

  • ARRO Educator of the year, Fox Chase Cancer Center 2013
  • Practical Radiation Oncology, Certificate in Excellence of Reviewing, 2013

    Treatment Philosophy

    I joined Fox Chase after completing my residency at the University of Florida in 2010. I specialize in treating cancers of the head and neck and skin cancer.

    Cancer is a complicated, confusing diagnosis. Cancers of the head and neck are particularly challenging because they occur in areas that can affect our ability to perform some of our most basic functions: breathing, speaking, and eating.

    I came to Fox Chase because I believe that the best way to cure these difficult cancers while maintaining quality of life is through a multi-disciplinary approach. Some cancers are cured with radiation alone, some need the assistance of both surgery and chemotherapy, and some are cured without radiation. The team approach at Fox Chase ensures that many different disciplines are working together to decide the best treatment for your unique case with one unifying goal: curing your cancer while avoiding unnecessary toxicity

    Education and Training

    Educational Background

    • MD, University of Florida, Gainesville, FL, 2005
    • BS, Chemistry, University of Florida, Gainesville, FL, 2001

    Certifications

    • American Board of Radiology
    • Radiation Oncology

    Memberships

    • American Society of Therapeutic Radiology (ASTRO)
    • Radiation Therapy Oncology Group (RTOG)
    • Institutional Principal Investigator for Fox Chase Cancer Center (Institution 2212) July 2013 - Present
    • American Radium Society (ARS)
    • Radiological Society of North America (RSNA)
    • American College of Radiology (ACR)
    • Eastern Cooperative Oncology Group (ECOG)

      Honors & Awards

      • ARRO Educator of the year, Fox Chase Cancer Center 2013
      • Practical Radiation Oncology, Certificate in Excellence of Reviewing, 2013
      Patient Stories

      Jack Gullo

      Head & Neck Cancer

      Jack Gullo

      Head & Neck Cancer

      A few days before leaving on my vacation in August, 2017, I noticed a loose tooth. My biggest worry was that maybe I had an abscess and it would ruin my trip.

      When I got home, my dentist said I should have it pulled, so I went to an oral surgeon. The oral surgeon said, “I see something, so I’m going to do a biopsy.” I kind of knew right then that I had cancer.

      Linda Rathbun

      Head & Neck Cancer

      Linda Rathbun

      Head & Neck Cancer

      I tell people if you are going on this journey, you should not compare yourself to anyone else. Every cancer is different, and every person’s situation is different.

      Tierra Ryan

      Lymphoma

      Tierra Ryan

      Lymphoma

      At 31, Tierra Ryan was a young professional woman, working as a pharmacist and a medical writer for a large pharmaceutical company, when she was shocked to learn she was diagnosed with Hodgkin's lymphoma. Fox Chase Cancer Center was one of two hospitals her doctor recommended. Tierra underwent chemotherapy and radiation therapy at Fox Chase, and in November 2014 was placed on surveillance because her cancer was in remission. Today, she still works in the pharmaceutical industry, but as a medical science liaison focusing on oncology. "I’m truly thankful to the doctors and staff at Fox Chase because they saved my life," Tierra said. "Because of them, I have a long life ahead of me."

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

       

      Stephen Meier

      Head & Neck Cancer

      Stephen Meier

      Head & Neck Cancer

      "I’m the kind of person who isn’t prone to panic. Panic just causes confusion. So, when what began as soreness on the right side of my throat turned out to be cancer, I remained calm and figured somebody can fix it."

      Paul Reitano

      Head & Neck Cancer

      Paul Reitano

      Head & Neck Cancer

      Paul Reitano was an active 45-year-old male with two careers, who was looking to start a family with his wife. After getting an initial diagnosis of squamous cell carcinoma from an ENT at a local hospital, Paul and his wife decided to seek a second opinion from Fox Chase Cancer Center. After Paul learned he actually had HPV tonsil cancer, not squamous cell carcinoma, he sought radiation therapy, chemotherapy, and surgery at Fox Chase with the help of Dr. Thomas Galloway. Today he is cancer free. "Not a day goes by since then that I am not grateful that I chose Fox Chase for my care," Paul said. "There was a real comfort in Fox Chase, I trusted them completely.  The decision to be treated by Fox Chase saved my life and allowed me to give life to a little girl."

      Pages

      Research Profile

      Research Program

      Research Interests

      • Head and neck cancer
      • Head and neck cancer survivorship
      • Skin Cancer (both melanoma and non-melanoma)
      • Merkel Cell Carcinoma Radiation target delineation
      • Pre-treatment imaging evaluation beyond the diagnosis
      • Impact of time to treatment in the curative management of head and neck cancer
      Publications

      Selected Publications

      Ebersole B., McCarroll L., Ridge J.A., Liu J.C., Bauman J., Donnelly S., Galloway T.J., Identification and management of late dysfunction in survivors of head and neck cancer: Implementation and outcomes of an interdisciplinary quality of life (iqol) clinic. Head Neck. 43(7): 2124-2135, 2021. https://www.ncbi.nlm.nih.gov/pubmed/33749012.

      Lee C.T., Galloway T.J., Pathogenesis and amelioration of radiation-induced oral mucositis. Curr Treat Options Oncol. 23(3): 311-324, 2022. PMC8931694. https://www.ncbi.nlm.nih.gov/pubmed/35244887.

      Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. The Survival Impact of Increasing Time to Treatment Initiation for Patients with Head and Neck Cancer in the United States. Accepted for publication in Journal of Clinical Oncology PubMed

      Murphy CT, Devarajan K, Wang LS, Mehra R, Ridge JA, Fundakowski C, Galloway TJ. Pre-Treatment Tumor-Specific Growth Rate as a Temporal Biomarker that Predicts Treatment Failure and Improves Risk Stratification for Oropharyngeal Cancer. Accepted for publication in Oral Oncology PubMed

      Lango MN, Galloway TJ, Mehra R, Ebersole B, Liu JC, Burtness B, Moran K, Ridge JA.  Impact of baseline dysphagia on acute feeding tube placement in head and neck cancer patients undergoing definitive radiation.  Epub ahead of print in Head and Neck PubMed

      Galloway TJ, Ridge JA.  Management of squamous cancer metastatic to cervical nodes with unknown primary.  Epub ahead of print in Journal of Clinical Oncology PubMed

      Galloway TJ, Wirth L, Colevas D, Gilbert J, Bauman J, Saba N, Raben D, Mehra R, Burtness B, Jimeno A. A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma (Clinical Cancer Research 2015; 21(7) 1566-1573). PubMed

      Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. Increasing time to treatment initiation for squamous cell carcinoma of the head and neck: An analysis of the National Cancer Database. (Cancer 2015; 121(8) 1204-1213). PubMed

      Nguyen-Tan PF, Zhang QE, Ang KK, Wheeler RH, Weber RS, Rosenthal DI, Bahary JP, Kim H, Silverman C, Raben A, Galloway T, Vigneault E, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. A Randomized Phase III Trial to Test Accelerated versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Long Term Report of Efficacy and Toxicity. (Journal of Clinical Oncology 2014; 32(34) 3858-3867 

      Lango MN, Egleston B, Fang CY, Burtness B, Galloway T, Liu JC, Mehra R, Ebersole B, Moran KM, Ridge JA. Baseline Health Perceptions, weight-loss and survival in head and neck cancer. (Cancer 2014; 120(6):840-7... Expand

      Additional Publications

      My NCBI

      Ratings

      77 PATIENT SATISFACTION REVIEWS

      Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.

      OVERALL RATING

      4.8 / 5.0

      RATINGS BREAKDOWN

      • 4.8
      • 4.8
      • 4.9
      • 4.9
      • 4.8

      13 PATIENT COMMENTS

      • 5.0
        May 27, 2022
        Excellent care from Dr. Galloway & his team. His nurse [...] is very caring & responsive. Dr. G. is very thorough and spends lots of time with the patient to ensure we understand things.
      • 5.0
        May 20, 2022
        Excellent experience
      • 5.0
        April 28, 2022
        Technician problems, otherwise dr. was very caring, informative - was put somewhat at ease.
      • 5.0
        April 15, 2022
        Good!!
      • 5.0
        March 28, 2022
        I can not say enough good things about Dr. Galloway and the entire team who have been with me since the beginning of my cancer journey. They saved my life and have always treated me with respect and dignity. The genuine concern for my overall well being has comforted me throughout this journey!!!
      • 5.0
        November 27, 2021
        Great experience Dr Galloway and his staff are the best!
      • 5.0
        September 14, 2021
        Very nice experience great doctor, have been a patient a long time
      • 5.0
        July 30, 2021
        AN EXCELLENT DOCTOR, ALONG WITH [...], ONE OF THE NURSES!
      • 5.0
        July 28, 2021
        Dr. Galloway is a very informative and attentive Doctor. He gives excellent care.
      • 5.0
        July 16, 2021
        Extremely informative, caring and would do whatever it takes to make your visit comfortable.
      • 5.0
        July 02, 2021
        Very good & pleasant visit.
      • 5.0
        May 21, 2021
        Dr. Galloway and his staff were always pleasant and up beat, full of energy.
      • 5.0
        May 21, 2021
        Dr. Galloway and his team are wonderful - caring, pleasant, and thorough.
      LOAD MORE
      Thomas Galloway, MD

      Clinical Locations

      Primary Location

      Fox Chase Cancer Center
      333 Cottman Avenue
      Philadelphia, PA 19111

      4.8
      77 Patient Satisfaction Ratings

      Associate Professor, Department of Radiation Oncology

      Chief, Division of Head and Neck Radiation Oncology

      Medical Director, Clinical Research

       

      Specialties

      Head & Neck Cancer;  Melanoma;  Skin Cancer;  Thyroid Cancer

      Treatment Focus

      • Intensity modulated radiation therapy
      • Stereotactic body radiation therapy
      • Modulated electron beam therapy
      • Interstitial brachytherapy
      • Rotational arc therapy

      Research Program

      Key Awards

      • ARRO Educator of the year, Fox Chase Cancer Center 2013
      • Practical Radiation Oncology, Certificate in Excellence of Reviewing, 2013

        Treatment Philosophy

        I joined Fox Chase after completing my residency at the University of Florida in 2010. I specialize in treating cancers of the head and neck and skin cancer.

        Cancer is a complicated, confusing diagnosis. Cancers of the head and neck are particularly challenging because they occur in areas that can affect our ability to perform some of our most basic functions: breathing, speaking, and eating.

        I came to Fox Chase because I believe that the best way to cure these difficult cancers while maintaining quality of life is through a multi-disciplinary approach. Some cancers are cured with radiation alone, some need the assistance of both surgery and chemotherapy, and some are cured without radiation. The team approach at Fox Chase ensures that many different disciplines are working together to decide the best treatment for your unique case with one unifying goal: curing your cancer while avoiding unnecessary toxicity

        Education

        Educational Background

        • MD, University of Florida, Gainesville, FL, 2005
        • BS, Chemistry, University of Florida, Gainesville, FL, 2001

        Certifications

        • American Board of Radiology
        • Radiation Oncology

        Memberships

        • American Society of Therapeutic Radiology (ASTRO)
        • Radiation Therapy Oncology Group (RTOG)
        • Institutional Principal Investigator for Fox Chase Cancer Center (Institution 2212) July 2013 - Present
        • American Radium Society (ARS)
        • Radiological Society of North America (RSNA)
        • American College of Radiology (ACR)
        • Eastern Cooperative Oncology Group (ECOG)

          Honors & Awards

          • ARRO Educator of the year, Fox Chase Cancer Center 2013
          • Practical Radiation Oncology, Certificate in Excellence of Reviewing, 2013

          Research Profile

          Research Interests

          • Head and neck cancer
          • Head and neck cancer survivorship
          • Skin Cancer (both melanoma and non-melanoma)
          • Merkel Cell Carcinoma Radiation target delineation
          • Pre-treatment imaging evaluation beyond the diagnosis
          • Impact of time to treatment in the curative management of head and neck cancer

          Publications

          Selected Publications

          Ebersole B., McCarroll L., Ridge J.A., Liu J.C., Bauman J., Donnelly S., Galloway T.J., Identification and management of late dysfunction in survivors of head and neck cancer: Implementation and outcomes of an interdisciplinary quality of life (iqol) clinic. Head Neck. 43(7): 2124-2135, 2021. https://www.ncbi.nlm.nih.gov/pubmed/33749012.

          Lee C.T., Galloway T.J., Pathogenesis and amelioration of radiation-induced oral mucositis. Curr Treat Options Oncol. 23(3): 311-324, 2022. PMC8931694. https://www.ncbi.nlm.nih.gov/pubmed/35244887.

          Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. The Survival Impact of Increasing Time to Treatment Initiation for Patients with Head and Neck Cancer in the United States. Accepted for publication in Journal of Clinical Oncology PubMed

          Murphy CT, Devarajan K, Wang LS, Mehra R, Ridge JA, Fundakowski C, Galloway TJ. Pre-Treatment Tumor-Specific Growth Rate as a Temporal Biomarker that Predicts Treatment Failure and Improves Risk Stratification for Oropharyngeal Cancer. Accepted for publication in Oral Oncology PubMed

          Lango MN, Galloway TJ, Mehra R, Ebersole B, Liu JC, Burtness B, Moran K, Ridge JA.  Impact of baseline dysphagia on acute feeding tube placement in head and neck cancer patients undergoing definitive radiation.  Epub ahead of print in Head and Neck PubMed

          Galloway TJ, Ridge JA.  Management of squamous cancer metastatic to cervical nodes with unknown primary.  Epub ahead of print in Journal of Clinical Oncology PubMed

          Galloway TJ, Wirth L, Colevas D, Gilbert J, Bauman J, Saba N, Raben D, Mehra R, Burtness B, Jimeno A. A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma (Clinical Cancer Research 2015; 21(7) 1566-1573). PubMed

          Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. Increasing time to treatment initiation for squamous cell carcinoma of the head and neck: An analysis of the National Cancer Database. (Cancer 2015; 121(8) 1204-1213). PubMed

          Nguyen-Tan PF, Zhang QE, Ang KK, Wheeler RH, Weber RS, Rosenthal DI, Bahary JP, Kim H, Silverman C, Raben A, Galloway T, Vigneault E, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. A Randomized Phase III Trial to Test Accelerated versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Long Term Report of Efficacy and Toxicity. (Journal of Clinical Oncology 2014; 32(34) 3858-3867 

          Lango MN, Egleston B, Fang CY, Burtness B, Galloway T, Liu JC, Mehra R, Ebersole B, Moran KM, Ridge JA. Baseline Health Perceptions, weight-loss and survival in head and neck cancer. (Cancer 2014; 120(6):840-7... Expand

          Additional Publications

          My NCBI

          Related Articles

          Head and Neck Cancer Survivors Could Benefit From...
          Fox Chase Researchers Find Association Between Rapid...
          Fox Chase Researchers Find Care of Head and Neck Cancer...
          The median time to cranial neuropathy was more than seven years, with some patients developing cranial neuropathy more than 10 years later.
          Radiation-Induced Cranial Neuropathy Occurred Up to 10...
          “It is sometimes human nature to think that more is better, and the guidelines on the topic have a range of doses with no specific recommendation,” said Dr. Galloway. “However, according to this data, there is no evidence to support routine dose escalation in the adjuvant radiation of head and neck cancer patients.”
          Postoperative Radiation Dose Escalation Not Necessary for...

          Connect with Fox Chase